Characterization by Quantitative Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 Symptomatology

Frontiers in Immunology

卷:12

Margarita Villar¹  Agustín Estrada-Peña²  José de la Fuente³  Natalia Jiménez-Collados⁴  Marinela Contreras⁵  Francisco J. Rodríguez-del-Río⁶  José Miguel Urra⁷  Elisa Ferreras-Colino⁸  Sara Artigas-Jerónimo⁸  Christian Gortázar⁸  Isabel G. Fernández de Mera⁸ 

[1] Biochemistry Section, Faculty of Science and Chemical Technologies, and Regional Centre for Biomedical Research, University of Castilla-La Mancha, Ciudad Real, Spain;

[2] Department of Animal Pathology, Faculty of Veterinary Medicine, University of Zaragoza, Zaragoza, Spain;

[3] Department of Veterinary Pathobiology, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, OK, United States;

[4] Immunology, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain;

[5] Interdisciplinary Laboratory of Clinical Analysis, Interlab-UMU, University of Murcia, Murcia, Spain;

[6] Local Medical Service Horcajo de los Montes, Ciudad Real, Spain;

[7] Medicine School, Universidad de Castilla la Mancha, Ciudad Real, Spain;

[8] SaBio, Instituto de Investigación en Recursos Cinegéticos IREC-CSIC-UCLM-JCCM, Ciudad Real, Spain;

关键词: COVID-19;    proteomic;    immunology;    biomarker;    diagnostic;    prognostic;   

DOI  :  10.3389/fimmu.2021.730710

来源: DOAJ

【 摘 要 】

The COVID-19 pandemic caused by SARS-CoV-2 challenges the understanding of factors affecting disease progression and severity. The identification of prognostic biomarkers and physiological processes associated with disease symptoms is relevant for the development of new diagnostic and therapeutic interventions to contribute to the control of this pandemic. To address this challenge, in this study, we used a quantitative proteomics together with multiple data analysis algorithms to characterize serum protein profiles in five cohorts from healthy to SARS-CoV-2-infected recovered (hospital discharge), nonsevere (hospitalized), and severe [at the intensive care unit (ICU)] cases with increasing systemic inflammation in comparison with healthy individuals sampled prior to the COVID-19 pandemic. The results showed significantly dysregulated proteins and associated biological processes and disorders associated to COVID-19. These results corroborated previous findings in COVID-19 studies and highlighted how the representation of dysregulated serum proteins and associated BPs increases with COVID-19 disease symptomatology from asymptomatic to severe cases. The analysis was then focused on novel disease processes and biomarkers that were correlated with disease symptomatology. To contribute to translational medicine, results corroborated the predictive value of selected immune-related biomarkers for disease recovery [Selenoprotein P (SELENOP) and Serum paraoxonase/arylesterase 1 (PON1)], severity [Carboxypeptidase B2 (CBP2)], and symptomatology [Pregnancy zone protein (PZP)] using protein-specific ELISA tests. Our results contributed to the characterization of SARS-CoV-2–host molecular interactions with potential contributions to the monitoring and control of this pandemic by using immune-related biomarkers associated with disease symptomatology.

【 授权许可】

Unknown